Developer docs
API playgroundTry for free, no card

Search company profiles

AC Immune

Full company profile

uuid0000zc9

Namestring
AC Immune
Legal namestring
AC Immune SA
Websiteurl
acimmune.com
Company typeenum
Public
Founded yearint
2003
Descriptiontext

AC Immune SA is a clinical-stage biopharmaceutical company headquartered at the EPFL Innovation Park in Lausanne, Switzerland, developing precision medicines and diagnostics for neurodegenerative diseases including Alzheimer's, Parkinson's, and rare NeuroOrphan indications. The company's pipeline is built on two proprietary technology platforms: the SupraAntigen® liposome-based platform for active and passive immunotherapies targeting misfolded proteins, and the Morphomer® small molecule chemistry platform (a library of approximately 10,000 CNS-optimized non-dye compounds) for aggregation inhibitors. Clinical and preclinical candidates include anti-pTau immunotherapy ACI-35.030, anti-Abeta immunotherapy ACI-24.060, anti-alpha-synuclein immunotherapy ACI-7104.056, brain-penetrant NLRP3 inhibitor ACI-19764, and first-in-class PET tracers for Tau (PI-2620), TDP-43 (ACI-19626) and alpha-synuclein (ACI-12589).

AC Immune operates an asset-light, partnership-driven business model: the company out-licenses candidates to major pharmaceutical partners at optimal development stages in exchange for upfront payments, development/regulatory/commercial milestones, and tiered royalties. Named partners include Janssen Pharmaceuticals (ACI-35.030; up to CHF 500M plus royalties), Eli Lilly (Morphomer Tau; up to CHF 1.9B with April 2026 amendment adding CHF 10M upfront and >CHF 1.7B in potential milestones), Takeda (Abeta including ACI-24.060; $100M upfront, up to $2.1B plus double-digit royalties), and Lantheus (PI-2620; up to EUR 160M plus royalties). AC Immune reported CHF 3.6 million of contract revenues in FY2025 (down from CHF 27.3M in FY2024) with a net loss of CHF 70.5 million and CHF 91.4 million of cash as of December 2025, subsequently declining to CHF 74.8 million by March 2026 following a 30% workforce reduction intended to extend cash runway into Q3 2027. The company is listed on NASDAQ under ticker ACIU following a 2016 IPO and is led by Interim CEO Martin Zügel following founder Dr. Andrea Pfeifer's retirement in May 2026.

Short descriptiontext

AC Immune SA is a clinical-stage Swiss biopharmaceutical company developing precision immunotherapies, small molecule aggregation inhibitors, and PET diagnostics for neurodegenerative diseases including Alzheimer's, Parkinson's, and rare proteinopathies, monetizing its pipeline through out-licensing partnerships with Eli Lilly, Janssen, Takeda, and Lantheus.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersLausanne, Switzerland
HQ citystring
Lausanne
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neurodegenerative disease therapeutics, active immunotherapy development, PET tracer diagnostics, small molecule aggregation inhibitors, precision medicine biotech
Industry4 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Neurodegenerative Disease Therapeutics and Diagnostics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Partnership Milestones and Royalties
TypeLicensing Royalties
Description

AC Immune generates revenue through upfront payments, development/regulatory/commercial milestones, and tiered royalties from pharmaceutical partnerships. Over CHF 450 million has been generated through partnering activities to date.

acimmune.com
2Grant Funding
TypeLicensing Royalties
Description

Non-dilutive funding from charitable foundations for specific research programs, such as the $4 million grant from The Vijay and Marie Goradia Charitable Foundation for Parkinson's disease trial extension.

ng.investing.com
3Equity Offering
TypeSubscription Recurring
Description

Clinical-stage company raising capital through equity offerings to fund research and clinical development. Completed USD 50.1 million equity offering in December 2023.

startupticker.ch
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1SupraAntigen
Description

Technology platform for developing active and passive immunotherapy candidates using liposomes to stimulate immune responses against misfolded proteins.

acimmune.com
+1 more record
Core offering1 text field

AC Immune is a clinical-stage biopharmaceutical company developing precision therapeutics and diagnostics for neurodegenerative diseases, including Alzheimer's, Parkinson's, and rare neuro indications. The company leverages two proprietary technology platforms—SupraAntigen® for liposome-based immunotherapies and Morphomer® for CNS-penetrant small molecules—to generate a diversified pipeline of active immunotherapies, monoclonal antibodies, small molecule inhibitors, and PET imaging tracers, which it out-licenses to global pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Over CHF 450 million generated through partnering activities
+4 more records
Product overview1 text field

AC Immune is a clinical-stage biopharmaceutical company with a diversified pipeline of therapeutic and diagnostic candidates focused on neurodegenerative diseases. The company's product portfolio includes active immunotherapies (ACI-35.030, ACI-24.060, ACI-7104.056), small molecule inhibitors (ACI-19764), and diagnostic PET tracers (PI-2620, ACI-19626). These products are powered by two proprietary technology platforms: SupraAntigen® for liposome-based immunotherapies and antibodies, and Morphomer® for small molecule aggregation inhibitors. The company maintains strategic partnerships with Janssen (ACI-35.030), Takeda (ACI-24.060), Eli Lilly (Morphomer Tau), and Lantheus (PI-2620).

Product and service7 records
1ACI-35.030 (JNJ-2056)
CategoryTherapeutic candidate
Description

First-in-class anti-pTau active immunotherapy candidate designed to elicit antibodies against extracellular phosphorylated Tau to prevent and reduce the spread of Tau pathology in Alzheimer's disease; partnered with Janssen Pharmaceuticals.

2ACI-24.060
CategoryTherapeutic candidate
Description

Anti-Abeta active immunotherapy designed to generate antibodies specifically targeting misfolded Abeta, including oligomeric and pyroglutamate forms, to prevent accumulation and enhance clearance of amyloid plaques in Alzheimer's disease; partnered with Takeda.

3ACI-7104.056
CategoryTherapeutic candidate
Description

Anti-alpha-synuclein active immunotherapy for early Parkinson's disease that generates target-specific antibody response against pathological oligomeric alpha-synuclein to inhibit spreading and downstream neurodegeneration.

4ACI-19764
CategoryTherapeutic candidate
Description

Brain-penetrant NLRP3 inhibitor small molecule targeting the intracellular NLRP3 complex in microglia to inhibit production of pro-inflammatory factors for neuro-inflammation and neurodegenerative diseases.

5PI-2620
CategoryDiagnostic candidate
Description

Tau-PET tracer designed to specifically bind pathological forms of human Tau in Alzheimer's disease and other Tauopathies, crossing the blood-brain barrier with high selectivity including 4-repeat Tau isoforms; partnered with Lantheus (formerly Life Molecular Imaging).

6ACI-19626
CategoryDiagnostic candidate
Description

First-in-class TDP-43 PET tracer enabling imaging of TDP-43 pathology in the brain, with demonstrated higher brain uptake in ALS patients compared to healthy controls; intended for early diagnosis of TDP-43 proteinopathies including FTD, ALS, and LATE.

7ACI-12589
CategoryDiagnostic candidate
Description

Novel alpha-synuclein PET tracer designed to detect alpha-synuclein in patients with Parkinson's disease and other alpha-synucleinopathies.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1The Vijay and Marie Goradia Charitable Foundation
Strategic tierMinorTypeOthersAnnounced on2026-06-01
Description

$4 million research grant to extend Part 1 of Phase 2 VacSYn trial of ACI-7104 for early Parkinson's disease, funding an additional two years of safety and efficacy assessment. This is non-dilutive funding enabling continued development without financing.

in.investing.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-01
Description

Exclusive worldwide option and license agreement for AC Immune's active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24.060 for Alzheimer's disease. AC Immune receives $100 million upfront payment and is eligible for option exercise fee and additional potential milestones of up to approximately $2.1 billion, plus tiered double-digit royalties on worldwide net sales.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-12-01
Description

License and collaboration agreement to research and develop Morphomer Tau small molecule aggregation inhibitors for Alzheimer's disease and other neurodegenerative diseases. AC Immune may receive payments totaling up to approximately CHF 1.9 billion plus royalties. Collaboration combines AC Immune's Morphomer platform with Lilly's clinical development expertise and commercial capabilities in CNS disorders. Amended in April 2026 to include CHF 10 million upfront payment and potential milestones exceeding CHF 1.7 billion.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2014-12-01
Description

Worldwide exclusive license agreement and research collaboration to develop and commercialize therapeutic vaccines targeting phosphorylated Tau for Alzheimer's disease and potentially other Tauopathies. Partnership value potentially up to CHF 500 million plus royalties. Partner launched first prevention trial for anti-pTau active immunotherapy in patients with preclinical AD.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2014-05-01
Description

Exclusive worldwide out-licensing agreement for Tau protein PET tracer PI-2620 supporting early diagnosis and clinical management of Alzheimer's disease and other Tau-related disorders such as progressive supranuclear palsy (PSP). Agreement includes upfront and sales milestone payments totaling up to EUR 160 million plus royalties. Lantheus acquired Life Molecular Imaging in August 2025.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

AC Immune is located at EPFL Innovation Park and collaborates regularly with academics from EPFL. The location provides access to a prolific pool of researchers and academic expertise in life sciences and technology.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Biogen is the largest commercial neurodegenerative biotech, with Leqembi (lecanemab) co-developed with Eisai for Alzheimer's. As a clinical-stage peer working in the same AD/Parkinson's space with amyloid and emerging tau assets, Biogen is the most relevant bellwether for AC Immune's late-stage clinical and partnership economics.

TypeDirect peer
Description

Prothena is a clinical-stage biotech focused on protein-misfolding therapeutics for neurodegenerative diseases, including tau and alpha-synuclein programs. AC Immune's SupraAntigen antibody work and Prothena's monoclonal antibody pipeline operate in the same disease biology, mirroring each other's competitive position across AD and PD.

TypeBroad incumbent
Description

Eli Lilly is a current AC Immune partner (Morphomer Tau, CHF 1.9B+ deal) and simultaneously the largest competitor in AD with Kisunla (donanemab) and remternetug. Lilly's combined partner/incumbent positioning makes it the most strategically coupled peer, with overlapping interests in tau-targeting therapeutics and diagnostics.

4Eisai Co., Ltd.
TypeBroad incumbent
Description

Eisai developed and co-commercializes Leqembi with Biogen and operates a deep late-stage AD pipeline (including anti-MTBR Tau and preclinical assets). As the global AD commercial incumbent, Eisai provides the strategic benchmark AC Immune's tau and amyloid programs must compete against for partnership value.

TypeBroad incumbent
Description

Roche is a prior AC Immune partner (crenezumab and semorinemab) and remains a major AD player through gantenerumab and a broad CNS pipeline. Roche's legacy of working with AC Immune and its competitive tau/Abeta programs make it an incumbent whose strategic priorities heavily influence AC Immune's milestone realization.

TypeDirect peer
Description

BioArctic is a Swedish clinical-stage neurodegenerative biotech that out-licensed lecanemab to Eisai/Biogen and continues to develop its own antibody pipeline against alpha-synuclein and Abeta. Its operating model — Swedish CNS biotech licensing to global pharma — is essentially AC Immune's template.

TypeEmerging player
Description

Cognition Therapeutics is a clinical-stage biotech developing small molecules for AD and dry AMD, with a Phase 2 Sligo trial targeting synaptic pathology. Its focus on alternative mechanisms in AD positions it as a smaller-scale emerging peer operating in overlapping clinical-stage neurodegenerative space.

8Cassava Sciences
TypeEmerging player
Description

Cassava Sciences is a clinical-stage biotech developing simufilam for Alzheimer's disease. While its mechanism differs (filamin A modulation), it competes for the same AD-focused investor capital and partner attention as AC Immune's late-stage assets.

TypeDirect peer
Description

Lantheus is the exclusive licensee of AC Immune's PI-2620 Tau-PET tracer following its 2025 acquisition of Life Molecular Imaging. As a major radiopharmaceutical and diagnostic imaging company, Lantheus is the most directly comparable diagnostic-partner peer — operating downstream of AC Immune's pipeline.

TypeEmerging player
Description

Cerveau Technologies develops and supplies Tau PET imaging ligands (including flortaucipir precursor MK-6240 and tau agent partnerships with pharma) for Alzheimer's and other neurodegenerative disease research and clinical use. It is the most directly comparable emerging PET-tracer peer, competing with AC Immune's PI-2620 in the same diagnostic niche.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AC Immune

Neurodegenerative Disease Therapeutics and Diagnosticsacimmune.com

AC Immune SA is a clinical-stage Swiss biopharmaceutical company developing precision immunotherapies, small molecule aggregation inhibitors, and PET diagnostics for neurodegenerative diseases including Alzheimer's, Parkinson's, and rare proteinopathies, monetizing its pipeline through out-licensing partnerships with Eli Lilly, Janssen, Takeda, and Lantheus.

What AC Immune does

AC Immune SA is a clinical-stage biopharmaceutical company headquartered at the EPFL Innovation Park in Lausanne, Switzerland, developing precision medicines and diagnostics for neurodegenerative diseases including Alzheimer's, Parkinson's, and rare NeuroOrphan indications. The company's pipeline is built on two proprietary technology platforms: the SupraAntigen® liposome-based platform for active and passive immunotherapies targeting misfolded proteins, and the Morphomer® small molecule chemistry platform (a library of approximately 10,000 CNS-optimized non-dye compounds) for aggregation inhibitors. Clinical and preclinical candidates include anti-pTau immunotherapy ACI-35.030, anti-Abeta immunotherapy ACI-24.060, anti-alpha-synuclein immunotherapy ACI-7104.056, brain-penetrant NLRP3 inhibitor ACI-19764, and first-in-class PET tracers for Tau (PI-2620), TDP-43 (ACI-19626) and alpha-synuclein (ACI-12589).

AC Immune operates an asset-light, partnership-driven business model: the company out-licenses candidates to major pharmaceutical partners at optimal development stages in exchange for upfront payments, development/regulatory/commercial milestones, and tiered royalties. Named partners include Janssen Pharmaceuticals (ACI-35.030; up to CHF 500M plus royalties), Eli Lilly (Morphomer Tau; up to CHF 1.9B with April 2026 amendment adding CHF 10M upfront and >CHF 1.7B in potential milestones), Takeda (Abeta including ACI-24.060; $100M upfront, up to $2.1B plus double-digit royalties), and Lantheus (PI-2620; up to EUR 160M plus royalties). AC Immune reported CHF 3.6 million of contract revenues in FY2025 (down from CHF 27.3M in FY2024) with a net loss of CHF 70.5 million and CHF 91.4 million of cash as of December 2025, subsequently declining to CHF 74.8 million by March 2026 following a 30% workforce reduction intended to extend cash runway into Q3 2027. The company is listed on NASDAQ under ticker ACIU following a 2016 IPO and is led by Interim CEO Martin Zügel following founder Dr. Andrea Pfeifer's retirement in May 2026.

AC Immune firmographics

Firmographics
Name
AC Immune
Legal name
AC Immune SA
Website
https://acimmune.com
Company type
Public
Founded year
2003
Operating status
Operating
Headcount range
101–250 employees
Short description
AC Immune SA is a clinical-stage Swiss biopharmaceutical company developing precision immunotherapies, small molecule aggregation inhibitors, and PET diagnostics for neurodegenerative diseases including Alzheimer's, Parkinson's, and rare proteinopathies, monetizing its pipeline through out-licensing partnerships with Eli Lilly, Janssen, Takeda, and Lantheus.
Ownership category
akta.pro rank

AC Immune industry classification

Industry
Product category
Neurodegenerative Disease Therapeutics and Diagnostics
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Neurodegenerative disease therapeutics
  • Active immunotherapy development
  • PET tracer diagnostics
  • Small molecule aggregation inhibitors
  • Precision medicine biotech

Where AC Immune is headquartered

Location

Headquarters

HQ city
Lausanne
HQ country
Switzerland
HQ region
Europe

Offices2 records

Markets served

AC Immune business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Partnership Milestones and Royalties: AC Immune generates revenue through upfront payments, development/regulatory/commercial milestones, and tiered royalties from pharmaceutical partnerships. Over CHF 450 million has been generated through partnering activities to date.
  2. Grant Funding: Non-dilutive funding from charitable foundations for specific research programs, such as the $4 million grant from The Vijay and Marie Goradia Charitable Foundation for Parkinson's disease trial extension.
  3. Equity Offering: Clinical-stage company raising capital through equity offerings to fund research and clinical development. Completed USD 50.1 million equity offering in December 2023.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

AC Immune product offering

Product offering

Core offering

AC Immune is a clinical-stage biopharmaceutical company developing precision therapeutics and diagnostics for neurodegenerative diseases, including Alzheimer's, Parkinson's, and rare neuro indications. The company leverages two proprietary technology platforms—SupraAntigen® for liposome-based immunotherapies and Morphomer® for CNS-penetrant small molecules—to generate a diversified pipeline of active immunotherapies, monoclonal antibodies, small molecule inhibitors, and PET imaging tracers, which it out-licenses to global pharmaceutical partners.

Product overview

AC Immune is a clinical-stage biopharmaceutical company with a diversified pipeline of therapeutic and diagnostic candidates focused on neurodegenerative diseases. The company's product portfolio includes active immunotherapies (ACI-35.030, ACI-24.060, ACI-7104.056), small molecule inhibitors (ACI-19764), and diagnostic PET tracers (PI-2620, ACI-19626). These products are powered by two proprietary technology platforms: SupraAntigen® for liposome-based immunotherapies and antibodies, and Morphomer® for small molecule aggregation inhibitors. The company maintains strategic partnerships with Janssen (ACI-35.030), Takeda (ACI-24.060), Eli Lilly (Morphomer Tau), and Lantheus (PI-2620).

Differentiator

Problem solved

Functional benefit

Brands

  • SupraAntigen: Technology platform for developing active and passive immunotherapy candidates using liposomes to stimulate immune responses against misfolded proteins.
  • Morphomer

Products and services

  • ACI-35.030 (JNJ-2056) First-in-class anti-pTau active immunotherapy candidate designed to elicit antibodies against extracellular phosphorylated Tau to prevent and reduce the spread of Tau pathology in Alzheimer's disease; partnered with Janssen Pharmaceuticals.
  • ACI-24.060 Anti-Abeta active immunotherapy designed to generate antibodies specifically targeting misfolded Abeta, including oligomeric and pyroglutamate forms, to prevent accumulation and enhance clearance of amyloid plaques in Alzheimer's disease; partnered with Takeda.
  • ACI-7104.056 Anti-alpha-synuclein active immunotherapy for early Parkinson's disease that generates target-specific antibody response against pathological oligomeric alpha-synuclein to inhibit spreading and downstream neurodegeneration.
  • ACI-19764 Brain-penetrant NLRP3 inhibitor small molecule targeting the intracellular NLRP3 complex in microglia to inhibit production of pro-inflammatory factors for neuro-inflammation and neurodegenerative diseases.
  • PI-2620 Tau-PET tracer designed to specifically bind pathological forms of human Tau in Alzheimer's disease and other Tauopathies, crossing the blood-brain barrier with high selectivity including 4-repeat Tau isoforms; partnered with Lantheus (formerly Life Molecular Imaging).
  • ACI-19626 First-in-class TDP-43 PET tracer enabling imaging of TDP-43 pathology in the brain, with demonstrated higher brain uptake in ALS patients compared to healthy controls; intended for early diagnosis of TDP-43 proteinopathies including FTD, ALS, and LATE.
  • ACI-12589 Novel alpha-synuclein PET tracer designed to detect alpha-synuclein in patients with Parkinson's disease and other alpha-synucleinopathies.

Quantifiable outcome

  • Over CHF 450 million generated through partnering activities
  • +4 more outcomes

Companies that use AC Immune

Customer profile

Named customers4 records

Segments2 records

Ideal customer profiles2 records

AC Immune technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

AC Immune partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered minor and core.

  • The Vijay and Marie Goradia Charitable FoundationminorOthers · 1 June 2026$4 million research grant to extend Part 1 of Phase 2 VacSYn trial of ACI-7104 for early Parkinson's disease, funding an additional two years of safety and efficacy assessment. This is non-dilutive funding enabling continued development without financing.
  • TakedacoreStrategic or Co-development Partner · 1 May 2024Exclusive worldwide option and license agreement for AC Immune's active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24.060 for Alzheimer's disease. AC Immune receives $100 million upfront payment and is eligible for option exercise fee and additional potential milestones of up to approximately $2.1 billion, plus tiered double-digit royalties on worldwide net sales.
  • Eli Lilly and CompanycoreStrategic or Co-development Partner · 1 December 2018License and collaboration agreement to research and develop Morphomer Tau small molecule aggregation inhibitors for Alzheimer's disease and other neurodegenerative diseases. AC Immune may receive payments totaling up to approximately CHF 1.9 billion plus royalties. Collaboration combines AC Immune's Morphomer platform with Lilly's clinical development expertise and commercial capabilities in CNS disorders. Amended in April 2026 to include CHF 10 million upfront payment and potential milestones exceeding CHF 1.7 billion.
  • Janssen PharmaceuticalscoreStrategic or Co-development Partner · 1 December 2014Worldwide exclusive license agreement and research collaboration to develop and commercialize therapeutic vaccines targeting phosphorylated Tau for Alzheimer's disease and potentially other Tauopathies. Partnership value potentially up to CHF 500 million plus royalties. Partner launched first prevention trial for anti-pTau active immunotherapy in patients with preclinical AD.
  • Lantheus (formerly Life Molecular Imaging)coreStrategic or Co-development Partner · 1 May 2014Exclusive worldwide out-licensing agreement for Tau protein PET tracer PI-2620 supporting early diagnosis and clinical management of Alzheimer's disease and other Tau-related disorders such as progressive supranuclear palsy (PSP). Agreement includes upfront and sales milestone payments totaling up to EUR 160 million plus royalties. Lantheus acquired Life Molecular Imaging in August 2025.
  • EPFL (École Polytechnique Fédérale de Lausanne)coreStrategic or Co-development PartnerAC Immune is located at EPFL Innovation Park and collaborates regularly with academics from EPFL. The location provides access to a prolific pool of researchers and academic expertise in life sciences and technology.

Scale indicators10 records

Recent moves8 records

Expansion highlights5 records

AC Immune competitors and assessment

Company assessment

Direct peers

  • Biogen: Biogen is the largest commercial neurodegenerative biotech, with Leqembi (lecanemab) co-developed with Eisai for Alzheimer's. As a clinical-stage peer working in the same AD/Parkinson's space with amyloid and emerging tau assets, Biogen is the most relevant bellwether for AC Immune's late-stage clinical and partnership economics.
  • Prothena Corporation: Prothena is a clinical-stage biotech focused on protein-misfolding therapeutics for neurodegenerative diseases, including tau and alpha-synuclein programs. AC Immune's SupraAntigen antibody work and Prothena's monoclonal antibody pipeline operate in the same disease biology, mirroring each other's competitive position across AD and PD.
  • BioArctic AB: BioArctic is a Swedish clinical-stage neurodegenerative biotech that out-licensed lecanemab to Eisai/Biogen and continues to develop its own antibody pipeline against alpha-synuclein and Abeta. Its operating model — Swedish CNS biotech licensing to global pharma — is essentially AC Immune's template.
  • Lantheus Holdings: Lantheus is the exclusive licensee of AC Immune's PI-2620 Tau-PET tracer following its 2025 acquisition of Life Molecular Imaging. As a major radiopharmaceutical and diagnostic imaging company, Lantheus is the most directly comparable diagnostic-partner peer — operating downstream of AC Immune's pipeline.

Broad incumbents

  • Eli Lilly: Eli Lilly is a current AC Immune partner (Morphomer Tau, CHF 1.9B+ deal) and simultaneously the largest competitor in AD with Kisunla (donanemab) and remternetug. Lilly's combined partner/incumbent positioning makes it the most strategically coupled peer, with overlapping interests in tau-targeting therapeutics and diagnostics.
  • Eisai Co., Ltd. Eisai developed and co-commercializes Leqembi with Biogen and operates a deep late-stage AD pipeline (including anti-MTBR Tau and preclinical assets). As the global AD commercial incumbent, Eisai provides the strategic benchmark AC Immune's tau and amyloid programs must compete against for partnership value.
  • Roche / Genentech: Roche is a prior AC Immune partner (crenezumab and semorinemab) and remains a major AD player through gantenerumab and a broad CNS pipeline. Roche's legacy of working with AC Immune and its competitive tau/Abeta programs make it an incumbent whose strategic priorities heavily influence AC Immune's milestone realization.

Emerging players

  • Cognition Therapeutics: Cognition Therapeutics is a clinical-stage biotech developing small molecules for AD and dry AMD, with a Phase 2 Sligo trial targeting synaptic pathology. Its focus on alternative mechanisms in AD positions it as a smaller-scale emerging peer operating in overlapping clinical-stage neurodegenerative space.
  • Cassava Sciences: Cassava Sciences is a clinical-stage biotech developing simufilam for Alzheimer's disease. While its mechanism differs (filamin A modulation), it competes for the same AD-focused investor capital and partner attention as AC Immune's late-stage assets.
  • Cerveau Technologies: Cerveau Technologies develops and supplies Tau PET imaging ligands (including flortaucipir precursor MK-6240 and tau agent partnerships with pharma) for Alzheimer's and other neurodegenerative disease research and clinical use. It is the most directly comparable emerging PET-tracer peer, competing with AC Immune's PI-2620 in the same diagnostic niche.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

AC Immune social profiles

Digital presence

AC Immune financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AC Immune leadership team

Management profile

Number of profiles

Profiles1 record

AC Immune subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

AC Immune funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AC Immune M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AC Immune

What does AC Immune do?

AC Immune is a clinical-stage biopharmaceutical company developing precision therapeutics and diagnostics for neurodegenerative diseases, including Alzheimer's, Parkinson's, and rare neuro indications. The company leverages two proprietary technology platforms—SupraAntigen® for liposome-based immunotherapies and Morphomer® for CNS-penetrant small molecules—to generate a diversified pipeline of active immunotherapies, monoclonal antibodies, small molecule inhibitors, and PET imaging tracers, which it out-licenses to global pharmaceutical partners.

Is AC Immune a public or private company?

AC Immune is a public company. It is classified as public and is currently operating.

When was AC Immune founded?

AC Immune was founded in 2003. It employs 101 to 250 people.

Where is AC Immune based?

AC Immune is headquartered in Lausanne, Switzerland, in the Europe region.

How does AC Immune make money?

Three revenue lines are on record. Partnership Milestones and Royalties are the primary driver. The others are grant Funding and equity Offering.

Who are AC Immune's main competitors?

Direct peers on record are Biogen, Prothena Corporation, BioArctic AB and Lantheus Holdings. Broad incumbents are Eli Lilly, Eisai Co., Ltd. and Roche / Genentech. Emerging players are Cognition Therapeutics, Cassava Sciences and Cerveau Technologies.

Does AC Immune have an API?

No public API is recorded for AC Immune.

What industry is AC Immune in?

AC Immune's product category is Neurodegenerative Disease Therapeutics and Diagnostics. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAEAG, Therapeutic Vaccines (e.g., Cancer/Chronic Infection). Its NAICS code is 325412 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialAC Immune To Present At Jefferies Global Healthcare Conference 2026AC Immune will present at the Jefferies Global Healthcare Conference 2026. The company's lead program, ACI-7104, is in Phase 2 for early Parkinson's disease, targeting misfolded alpha-synuclein. It also has an NLRP3 inflammasome inhibitor in Phase 1 and collaborations with three major pharma companies.TradingViewAC Immune to Present at Jefferies Global Healthcare Conference 2026AC Immune's Interim CEO Martin Zügel will present and participate in a fireside chat at the Jefferies Global Healthcare Conference 2026 in London on November 18. The session will cover ACI-7104, an anti-alpha-synuclein immunotherapy in Phase 2 for early Parkinson's disease, and updates on the company's pipeline.Stock TitanAC Immune to present at Jefferies conference Nov. 18AC Immune will present at the Jefferies Global Healthcare Conference on November 18, 2026, with Interim CEO Martin Zügel. The session will cover its lead candidate ACI-7104, an anti-alpha-synuclein immunotherapy in Phase 2 for early Parkinson's disease, and updates on its pipeline.MarketScreenerAC Immune SA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026AC Immune SA reported Q3 2026 revenue of CHF 3.24 million and a net loss of CHF 8.75 million, both improving year-over-year. For the nine months, revenue was CHF 19.48 million and net loss CHF 21.68 million, also down from the prior year.YahooAC Immune: Q3 Earnings SnapshotAC Immune SA reported a third-quarter loss of $10.8 million, or 16 cents per share, with revenue of $4 million. The company's shares closed at $2.09, down from $3.18 a year earlier.Stock TitanAC Immune Q3 earnings: loss narrows to CHF 8.8MAC Immune reported a Q3 2026 net loss of CHF 8.8 million, down from CHF 15.9 million in the same period last year, with revenue of CHF 3.2 million. Cash resources of CHF 73.9 million provide runway into Q1 2028. The company expects further clinical data for ACI-7104 before year-end and for ACI-19764 in early 2027.MarketBeatAC Immune (NASDAQ:ACIU) Rating Lowered to "Hold" at Zacks ResearchZacks Research downgraded AC Immune from strong-buy to hold. The stock has a consensus Hold rating with a $7.50 price target, and the company reported Q2 EPS of $0.03, beating estimates. Analysts expect a -0.60 EPS for the current fiscal year.American Banking and Market NewsReviewing AC Immune (ACIU) and Its RivalsAC Immune's stock is 56% more volatile than the S&P 500, with 51.4% institutional ownership and a consensus price target of $7.50. The company beats peers on 9 of 13 factors, including higher revenue and earnings, and analysts see a 216.46% upside.MarketBeatAC Immune (ACIU) Expected to Release Earnings on TuesdayAC Immune is expected to report Q3 2026 earnings on Tuesday, November 3rd, with a conference call on Wednesday. Analysts estimate a loss of $0.22 per share and revenue of $0.33 million. The stock opened at $2.31, down 4.5%.Ticker ReportCritical Comparison: ImageneBio (NASDAQ:IMA) & AC Immune (NASDAQ:ACIU)AC Immune and ImageneBio are compared on analyst ratings, profitability, and institutional ownership. ImageneBio has a higher consensus price target ($29.00 vs $7.50) and lower beta (0.74 vs 1.56), while AC Immune beats on 7 of 13 factors. ImageneBio's lead product IMG-007 completed Phase 2a trials for atopic dermatitis and alopecia areata.